Antibacterial Agents TRIZ Cases

Beta-methyl carbapenem compounds stabilize the beta-lactam ring against hydrolysis, improving recovery rates and gram-negative activity.

Arginine-modified CAP37 peptides resolve scalability and purity contradictions, achieving 5-log bacterial reduction against resistant strains.

Macroporous resin adsorption isolates active saponins from ethanol extracts, resolving low yield and complex purification bottlenecks.

P10 peptide penetrates biofilms to kill microbes and neutralize endotoxins, overcoming antibiotic resistance.

Ethoxzolamide inhibits carbonic anhydrase activity to disrupt the PhoP/R regulon, offering a shorter treatment regimen for drug-resistant tuberculosis.

A PD-L1 peptide vaccine composition elicits specific T-cell responses against tumor cells.

Blocking hydroxyl groups prevents O-glycosidic bond hydrolysis, improving polysaccharide stability for vaccine production.

Engineering complementarity-determining regions enables ultra-high affinity parasteric binding to FimH, disrupting biofilm formation and treating infections.

Senkyunolide A reduces TNF-α and nitric oxide levels, addressing adverse effects of current anti-inflammatory therapies while controlling immune response.

Injectable peptide scaffold mitigates reperfusion injury while enhancing nitric oxide formation for improved left ventricular contractility.

Hydrophilic functional groups increase water solubility, reducing pill burden and improving patient compliance.

Combination vaccine compositions reduce antigen and aluminium doses to enhance patient safety without compromising immunoprotective effects.

Nitroxoline base addition salts improve aqueous solubility and stability, reducing dosing frequency.

Boron-based compounds inhibit Penicillin-Binding Proteins via covalent adducts, bypassing beta-lactamase hydrolysis.

A probiotic strain inhibits pathogenic bacteria growth and reduces cellular adhesion.

HBc-derived peptides kill drug-resistant bacteria by disrupting membranes, offering a therapeutic option with minimal toxicity to human cells.

A rosacea treatment combining vasoconstrictors with bacterial lysis to reduce inflammation.

The 5B6 surface marker enables cross-species antigen targeting to dendritic cells, eliminating the need for additional adjuvants in vaccine formulations.

A multi-strain lactic acid bacterial composition inhibits Salmonella typhimurium growth through competitive exclusion and antimicrobial substance production.

Controlled precipitation of rifaximin yields a stable pseudo-crystalline form with reduced impurities and consistent bioavailability.

Non-lactone carbocyclic modulators stabilize autoinducer head groups to enhance quorum sensing activity in Pseudomonas aeruginosa.

Carboxylic acid mixture and anionic surfactants maintain efficacy despite manure deactivation, reducing antibiotic resistance.

A genome mining approach identifies novel phosphonate natural products using the pepM gene as a biosynthetic marker.

A Podoviridae bacteriophage SAP-2 selectively kills Staphylococcus aureus through enzymatic cell wall lysis, avoiding multidrug resistance.

Fluorescence-activated cell sorting enriches Gram-positive bacteria for oral capsule formulations.

Macrocyclic peptides replace complex monoclonal antibodies with cost-effective small molecules that specifically inhibit PD-1/PD-L1 interactions.

Hydrolyzed linseed extract stimulates antimicrobial peptide expression, resolving the trade-off between pathogen resistance and commensal flora preservation.

Lactic acid bacteria composition inhibits E. coli adhesion to epithelial cells.

Incorporating uncoded amino acids into peptide sequences enhances selectivity against elastase while stimulating collagen synthesis to treat aging symptoms.

Organic molecules combine dienone and alkyne structures to release carbon monoxide under physiological conditions.

Short-chain fatty acid compositions modulate gut microbiota profiles to prevent respiratory syncytial virus infection.

Inositol hexakisphosphate analogs inhibit toxin self-cleavage to treat infections and reduce relapse rates from antibiotic resistance.

Chemical synthesis of antibiotic analogues overcomes low fermentation yields to treat carbapenem-resistant Gram-negative strains.

A eutectic mixture of pharmacologically active ingredients enhances pulmonary drug delivery through improved solubility and dissolution rates.

Novel avian astrovirus detection targets unique ORF1a nucleotide sequence inserts for precise pathogen identification.

Avirulent Salmonella Gallinarum variants serve as host cells for producing lytic bacteriophages without toxic remnants.

A multi-level risk assessment method evaluates microbial drug resistance risks from antibiotic residues in water environments.

Viscosity-increasing agents protect gallium compounds from stomach acid degradation to enhance oral bioavailability.

Blautia strains colonize the intestine to modulate gut microbiota, resolving lack of specific strain identification that prevents effective treatment.

Segmented inhibitor design modulates RIP1 and RIP3 activity to reduce necroptosis in neurodegenerative diseases.

An immunogenic composition uses Haemophilus influenzae polypeptides to induce targeted immune responses against bacterial pathogens.

Sequential polarity-based extraction isolates dLGG to reduce AST, ALT, and melanogenesis.

Modified transposase sequences boost integration efficiency in human cells, overcoming low activity limits of conventional systems.